Clinical trials: Severe Knee Osteoarthritis
Osteoarthritis, Knee, Pain, Knee
Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis
This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
- Trial name
- NCT03542838
- Testing
- Resiniferatoxin, Saline
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Sorrento Therapeutics, Inc.
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Alberta Hip and Knee Replacement Project
The study aims to determine if a New Arthroplasty Care Model, established on evidence-based medicine and best practices, will improve patient outcomes and improve cost effectiveness for patients with severe degenerative joint…
- Trial name
- NCT00277186
- Testing
- New Care Continuum
- Where
- Canada
- Volunteers
- 3,434 people
- Sponsor
- Alberta Bone and Joint Health Institute
Osteoarthritis, Knee
A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee
A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.
- Trial name
- NCT03513016
- Testing
- UBX0101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Unity Biotechnology, Inc.
Osteoarthritis of the Knee
A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe chronic pain - active as a mu agonist, but with inherent molecular properties designed to provide a unique clinical profile, including…
- Trial name
- NCT01619839
- Testing
- NKTR-181
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Nektar Therapeutics
Osteoarthritis
A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis
This is a Phase I, prospective, active-controlled, randomized, open-label, clinical trial designed to assess the safety and tolerability of single intra-articular injection of RegenoGel-SP for the treatment of OA.
- Trial name
- NCT02188771
- Testing
- intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- ProCore Ltd.
Chronic Pain, Osteoarthritis of the Knee
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to…
- Trial name
- NCT00531427
- Testing
- Buprenorphine
- Where
- 87 sites in United States
- Volunteers
- 567 people
- Sponsor
- Purdue Pharma LP
Osteo Arthritis Knee
Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis
The purpose of this study is to investigate the safety and effectiveness of bone marrow aspirate concentrate (BMAC) in patients with moderate to severe osteoarthritis of the knee.
- Trial name
- BMAC (NCT04716803)
- Testing
- Bone Marrow Aspirate Concentrate, Angel Concentrated Platelet Rich Plasma (cPRP) System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Osteoarthritis Of Knee
Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis
Primary aim: evaluate efficacy of subcutaneous injection of etanercept for moderate and severe knee osteoarthritis. Second aim: investigate the potentiality of serum cytokines (TNF-α, Interleukin 1-α (IL1-α), IL1-β, matrix…
- Trial name
- ESIETNKOA (NCT02722811)
- Testing
- Etanercept, Health education, exercise and diet guidance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Osteoarthritis, Knee
A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
- Trial name
- NCT04129944
- Testing
- UBX0101
- Where
- 20 sites in United States
- Volunteers
- 183 people
- Sponsor
- Unity Biotechnology, Inc.
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Knee Osteoarthritis, Knee Pain Chronic
Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA
It is hypothesized that a single Intra-articular Injection of TTAX03, 100mg in 2mL of saline, will have more benefit with respect to the proportion of responders 12 weeks post-injection than an equal volume of saline, based on…
- Conditions
- Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- Trial name
- NCT05079035
- Testing
- TTAX03, Saline
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- BioTissue Holdings, Inc
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Osteoarthritis
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.
- Trial name
- NCT00483977
- Testing
- Oxycodone, PF-000592379
- Where
- 21 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Pain, Osteoarthritis
Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.
- Trial name
- NCT00345787
- Testing
- Buprenorphine Transdermal System
- Where
- 28 sites in Japan
- Volunteers
- 262 people
- Sponsor
- Mundipharma K.K.
Osteoarthritis, Pain
Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine
The primary objective of this equivalence study is to evaluate the efficacy of Norspan® patches versus Tramadol in subjects with chronic, moderate to severe osteoarthritis pain of the hip, knee and/or lumbar spine.
- Trial name
- NCT00426647
- Testing
- Buprenorphine, Tramadol
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- Norpharma A/S